Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the programa Español de tratamiento en hematología pediatric-based protocol ALL-96

Journal of Clinical Oncology

Volumn 26, Issue 11, 2008, Pages 1843-1849

  Ribera, Josep Maŕa ^a   Oriol, Albert ^a   Sanz, Miguel Angel ^a   Tormo, Mar ^a   Fernández Abellán, Pascual ^a   Del Potro, Eloy ^a   Abella, Eugenia ^a   Bueno, Javier ^a   Parody, Ricardo ^a   Bastida, Pilar ^a   Grande, Carlos ^a   Heras, Inmaculada ^a   Bethencourt, Concepción ^a   Feliu, Evarist ^a   Ortega, Juan José ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; HYDROCORTISONE; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; TENIPOSIDE; VINCRISTINE; ANTINEOPLASTIC AGENT;

ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER RISK; CANCER SURVIVAL; CONTROLLED STUDY; DRUG FATALITY; FEBRILE NEUTROPENIA; FOLLOW UP; HEALTH PROGRAM; HUMAN; INFECTION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; NEUROTOXICITY; PRIORITY JOURNAL; TREATMENT OUTCOME; AGE; CHEMICALLY INDUCED DISORDER; CHILD; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; FEMALE; HEMATOLOGIC DISEASE; INFANT; LYMPHATIC LEUKEMIA; MALE; PRESCHOOL CHILD; PROGNOSIS;

ADOLESCENT; ADULT; AGE FACTORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPARAGINASE; CHILD; CHILD, PRESCHOOL; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DISEASE-FREE SURVIVAL; FEMALE; HEMATOLOGIC DISEASES; HUMANS; HYDROCORTISONE; INFANT; INFECTION; MALE; METHOTREXATE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PREDNISONE; PROGNOSIS; TREATMENT OUTCOME; VINCRISTINE;

EID: 42949166852     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.13.7265     Document Type: Article

References (29)

1. Pui CH, Evans WE: Treatment of acute lymphoblastic leukemia. N Engl J Med 354:166-178, 2006
2. Stock W, Satjer H, Dodge RK, et al: Outcome of adolescents and young adults with ALL: A comparison of Children's Cancer Group (CCG) and Cancer and Leukemia Group B (CALGB) regimens. Blood 96:476a, 2000 (abstr)
3. Boissel N, Auclerc M-F, Lheritier V, et al: Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol 21:774-780, 2003
4. de Bont JM, van der Holt B, Dekker AW, et al: Significant difference in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric vs adult protocols in the Netherlands. Leukemia 18:2032-2035, 2004
5. Ramanujachar R, Richards S, Hann I, et al: Adolescents with acute lymphoblastic leukaemia: Emerging from the shadow of paediatric and adult treatment protocols. Pediatr Blood Cancer 47:748-756, 2006
6. Ramanujachar R, Richards S, Hann I, et al: Adolescents with acute lymphoblastic leukaemia: Outcome on UK national paediatric (ALL97) and adult (UKALLXII/E2993) trials. Pediatr Blood Cancer 48:254-261, 2007
7. Schrøder H, Kjeldahl M, Boesen AM, et al: Acute lymphoblastic leukemia in adolescents between 10 and 19 years of age in Denmark. Dan Med Bull 53:76-79, 2006
8. Testi AM, Valsecchi MG, Conter V, et al: Difference in outcome of adolescents with acute lymphoblastic leukemia (ALL) enrolled in pediatric (AIEOP) and adult (GIMEMA) protocols. Blood 104:1954a, 2004 (abstr)
9. Hallböök H, Gustafsson G, Smedmyr B, et al: Treatment outcome in young adults and children >10 years of age with acute lymphoblastic leukemia in Sweden: A comparison between a pediatric protocol and an adult protocol. Cancer 107:1551-1561, 2006
10. Schiffer CA: Differences in outcome in adolescents with acute lymphoblastic leukemia: A consequence of better regimens? Better doctors? Both? J Clin Oncol 21:760-761, 2003
11. DeAngelo DJ: The treatment of adolescents and young adults with acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 2005:123-130, 2005
12. Sallan SE: Myths and lessons from the Adult/Pediatric Interface in Acute Lymphoblastic Leukemia. Hematology Am Soc Hematol Educ Program 128-132, 2006
13. DeAngelo DJ, Silverman LB, Couban S, et al: A multicenter phase II study using a dose intensified pediatric regimen in adults with untreated acute lymphoblastic leukaemia. Blood 108:526a, 2006 (abstr)
14. Storring JM, Brandwein J, Gupta V, et al: Treatment of adult acute lymphoblastic leukaemia (ALL) with amodified DFCI pediatric regimen: The Princess Margaret experience. Blood 108:316a, 2006 (abstr)
15. Huguet F, Raffoux E, Thomas X, et al: Towards a pediatric approach in adults with acute lymphoblastic leukemia: The GRAALL/2003 study. Blood 108:48a, 2006 (abstr)
16. Ribera JM, Oriol A, Bethencourt C, et al: Comparison of intensive chemotherapy, allogeneic or autologous stem cell transplantation as post-remission treatment for adult patients with high-risk acute lymphoblastic leukemia: Results of the PETHEMA ALL-93 trial. Haematologica 90:1346-1356, 2005
17. Ribera JM, Ortega JJ, Oriol A, et al: Comparison of intensive chemotherapy, allogeneic or autologous stem cell transplantation as post-remission treatment for children with very high-risk acute lymphoblastic leukemia: PETHEMA ALL-93 trial. J Clin Oncol 25:16-24, 2007
18. Bennett JM, Catovsky D, Daniel MT, et al: The morphologic classification of acute lymphoblastic leukaemia: Concordance among observers and clinical correlations. Br J Haematol 47:553-561, 1981
19. Mitelman F (ed): ISCN: An International System for Human Cytogenetic Nomenclature. Basel, Switzerland, Karger, 1995
20. Ortega JJ, Ribera JM, Oriol A, et al: Early and delayed consolidation chemotherapy significantly improves the outcome of children with intermediate-risk acute lymphoblastic leukemia. Final results of the prospective randomized PETHEMA ALL-89 trial. Haematologica 86:586-595, 2001
21. Kaplan GL, Meier P: Nonparametric estimation from incomplete observations. J Am Statist Assoc 53:457-481, 1958
22. 2/E in the log-rank test for survival data or tumour incidence data. Biometrics 29:579-584, 1973
23. Cox DR: Regression models and life tables. J Roy Stat Soc Series B 34:187-220, 1972
24. Piernas S, Sancho JM, Batlle M, et al: Myelopathy due to intrathecal chemotherapy in a patient with acute lymphoblastic leukaemia. Med Clin (Barc) 126:76, 2006
25. Raff T, Gokbuget N, Luschen S, et al: Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: Data from the GMALL 06/99 and 07/03 trials. Blood 109:910-915, 2007
26. Rowe JM, Buck G, Burnett AK, et al: Induction therapy for adults with acute lymphoblastic leukemia: Results of more than 1500 patients from the international ALL trial - MRC UKALL XII/ECOG E 2993. Blood 106:3760-3767, 2005
27. Bruggemann M, Raff T, Flohr T, et al: Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukaemia. Blood 107:1116-1123, 2006
28. Barry E, DeAngelo DJ, Neuberg D, et al: Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute ALL Consortium protocols. J Clin Oncol 25:813-819, 2007
29. Bleyer A, O'Leary M, Barr R, Ries LAG (eds): Cancer Epidemiology in Older Adolescents and Young Adults 15 to 29 years of Age, including SEER Incidence and Survival: 1975-2000. Bethesda, MD, National Cancer Institute, NIH Pub. No. 06-5767. Bethesda, MD 2006